What are Polivy's most common side effects?
Polivy (polatuzumab vedotin-piiq), used with bendamustine and rituximab for relapsed or refractory diffuse large B-cell lymphoma, has these frequent side effects from clinical trials (occurring in ≥20% of patients):
- Neutropenia (up to 42%)
- Thrombocytopenia (up to 36%)
- Anemia (up to 32%)
- Fatigue (up to 30%)
- Diarrhea (up to 26%)
- Peripheral neuropathy (up to 26%)
- Nausea (up to 25%)
- Decreased appetite (up to 22%)
- Pyrexia (up to 21%)
These rates come from the GO29365 trial data in the prescribing information.[1]
How severe are they and when do they occur?
Most are mild to moderate (Grade 1-2), but severe cases (Grade 3-4) hit neutropenia (41%), thrombocytopenia (27%), and anemia (15%). They often start within the first two cycles and may need dose delays or reductions. Peripheral neuropathy can be permanent in some cases.[1]
What side effects are patients reporting in real-world use?
Post-marketing reports match trial data but highlight infections (e.g., pneumonia in 13%) and infusion reactions. Fatigue and neuropathy top patient forums like those on Drugs.com, with some describing ongoing numbness months after stopping.[2]
How does Polivy compare to standard treatments?
Compared to bendamustine-rituximab alone, Polivy adds higher rates of neutropenia (42% vs 13%) and neuropathy (26% vs 0%), but improves survival. No direct head-to-head for other effects.[1]
Tips for managing side effects
Doctors recommend monitoring blood counts weekly, using growth factors for neutropenia, and early neuropathy checks. Report fever or worsening symptoms immediately to avoid complications like sepsis.[1]
[1]: Polivy Prescribing Information (Genentech, 2023)
[2]: Drugs.com - Polivy Side Effects